We are looking for ways to better incorporate Oxytocin titration into EPIC for L&D.
Currently we have a complicated procedure (with adjustments for full dose/half dose/low dose) that is linked out however we would like to better incorporate this into the EHR.

Has anyone had success building this out with discrete dosing fields at their institutions? Any details on your build would be helpful.

Thanks
Kelly Salzar

Has anyone been successful in standardizing to 1 size/drug/concentration for their OnQ pumps? We currently stock several different size pumps, and MDs order a myriad of concentrations of bupivacaine and ropivacaine. I would love to stock 1, maybe 2, sizes of pumps in just 1 concentration (0.2% ropivacaine) for anesthesiologists and surgeons to use. Any guidance is appreciated.

Has anyone been successful in standardizing to 1 size/drug/concentration for their OnQ pumps? We currently stock several different size pumps, and MDs order a myriad of concentrations of bupivacaine and ropivacaine. I would love to stock 1, maybe 2, sizes of pumps in just 1 concentration (0.2% ropivacaine) for anesthesiologists and surgeons to use. Any guidance is appreciated.

Hi everyone, wondering if there are any facilities out there who have built baclofen, intended for intrathecal administration, in there IV pump library? My health system currently has a request for it, very rare for use in baclofen weaning or due to implantable pump misadventures. My concern currently is that our pump vendor does not have the IT route as an FDA approved use of their pumps. If there are any sites that have implemented this build what additional strategies did you utilize (ie-Clinicla advisories on the pump, etc.). Thank you in advance for any responses.

I'm pretty sure I am not interpretting USP 795 correctly, and wanted to get others' input... It appears that if you are compounding a non-sterile liquid, and you do not have any stability information, it is OK to give it a BUD of up to 14 days in the fridge. (The table in the USP chapter is titled "Maximum BUD by Type of Preparation in the Absence of a USP-NF Compounded Preparation Monograph or CNSP-Specific Stability Information"). Fourteen days seems awfully generous.

I am reaching out to see what other facilities are doing in regards to low volume intermittent infusions in the NICU.
After our institution converted to Alaris from Medfusion Pumps in our Neonatal ICU, there was a lot of confusion on the process and questions of what is the best process for administering intermittent medications whose volumes were less than 0.8 mL (i.e., just enough volume to clear tubing + ports). We are currently priming to the baby and then running a flush at the rate of the medication however this is causing some confusion.

Hello all,

If your organization has outpatient oncology infusion centers, do you have any established metrics around error reporting? We are working with a multidisciplinary team on what that would look like and how we can normalize the data to compare sites of different sizes. Some studies report error rates per 100 clinic visits or 1,000 medication orders.

Does anyone have a similar metric for outpatient infusion error reporting?

Thanks,
Gina Gayed

Happy Friday,
Anyone successfully build an orderable to document an implanted pain pump (multicomponent) continued from home in EPIC? If yes, please can you share the order build to making it visible on the MAR and process for nursing documentation?

Thank you!

What is the return to pharmacy/ADC process look like at your institution? Do you have internal and/or external return bins for your ADCs whereby users/nurses return any unused medications to the return bin? Do you allow/expect returns to be done back to the ADC pockets by nursing? Do you have the same return process for controlled substances and non controlled substances?

Our organization is looking to move all doses of cefazolin, ceftriaxone, and cefepime to IVP. While this may work from a clinical and financial perspective, I'm concerned about the risks associated with moving from commercially-available products to pharmacy-compounded syringes (risk of error, contamination, expired product management, etc.).

Has any other large hospital or health system moved forward with this conversion and have some "lessons learned" to share with us? Thank you in advance!